TRANE-TECHNOLOGIES
17.8.2020 06:32:12 CEST | Business Wire | Press release
Global climate innovator Trane Technologies (NYSE: TT) announced today the launch of the Sintesis™ Balance CMAF, a fully electric single unit to heat and cool buildings. The air-cooled multi-pipe solution is the latest model in the Sintesis portfolio of high-performance indoor climate systems by Trane®, the company’s HVAC brand. It is initially available for customers in Europe, Middle East, and Africa.
Sintesis Balance is a fully electric unit that delivers hot and chilled water for heating and cooling. It is ideal for buildings with dynamic temperature requirements, such as schools, hotels, hospitals, retail centers, office buildings and theaters.
“The Sintesis Balance eliminates the need for separate boiler and chiller systems, and provides flexibility to meet comfort needs across climates, seasons, use and occupancy, as well as better use of floor space,” said José La Loggia, president of Trane Technologies’ Commercial HVAC in EMEA. “It also provides highly reliable operation, temperature control and indoor air quality. Most systems in Europe use gas or oil boilers, whereas this solution is fully electric. Since buildings contribute to about 15 percent of global carbon emissions, and heating and cooling represents about 35 percent of that, Sintesis Balance is also a major step on the path to electrification and decarbonization of buildings.”
The innovation contributes to Trane Technologies’ Gigaton Challenge, a goal to reduce customers’ greenhouse gas emissions by a billion metric tons by 2030. The unit recovers and repurposes energy without generating its own carbon emissions, significantly reducing fossil fuel use over typical systems that include both a boiler and a chiller. When drawing from a grid that generates electricity from renewable sources, Sintesis Balance has potential to be a zero-emissions solution.
Sintesis Balance Sustainability by the Numbers
Trane Sintesis Balance has an average Total Efficiency Ratio of 8.2; it generates 8 kW of simultaneous cooling and heating from only 1 kW of electric power. It also delivers a Coefficient of Performance (COP) of 3.35, the highest COP among air-sourced multi-pipe unit options. (COP is a measure of how much heat the system produces per unit of energy input).
The technology’s expanded operating map allows for temperature control even in very hot or cold climates. The heating capabilities of the unit make it a good choice for building applications in regions where ambient air temperatures go down to minus 18 degrees Celsius. The unit also can heat water up to 68 degrees Celsius.
Technical features of the Trane Sintesis Balance CMAF
- Trane Adaptive Refrigerant System™ automatically optimizes refrigerant charge in each operating mode and temperature condition, delivering additional performance and efficiency gains.
- Fully electric driven CMAF multi-pipe unit doesn’t generate direct greenhouse gas emissions beyond emissions from the electricity grid. It offers up to 350 percent higher efficiency compared to most gas boilers when delivering hot water for comfort heating systems.
- Configurability with three acoustic packages and efficiency levels to meet different building application requirements.
- New generation of Trane controls technology – Tracer Symbio™ 800 controller features advanced algorithms ensuring smooth, reliable operation with low cost of ownership. In addition, it also offers six arbitration choices to optimize performances for the application.
- Tracer Symbio 800 with TD7 AdaptiView™ touchscreen provides facility managers with user-friendly control of the unit. The controller allows them to remotely manage and respond to a variety of conditions and maintain efficient operation with various pre-programmed operating modes.
For more details of on the complete Trane portfolio of solutions for EMEA, please visit www.Trane.eu .
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. Visit tranetechnologies.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
